The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Eli Lilly (NYSE: LLY) stock has ripped higher off its post-earnings lows yet remains underwater for the year, which is exactly what the “Sell in May” crowd hunts for.

The bounce offers room for tactical positioning while preserving core franchise exposure.

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn't one of them. Get them here FREE.

The market adage "Sell in May and Go Away" rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim.

Lilly closed Monday at $966.99, up 2.9% over the past month and 31.6% over the past year, yet still down 10.0% year to date. That mismatch between a hot tape and a red YTD line is exactly what the "Sell in May" crowd hunts for.

The catalyst was a blowout Q1 report. Revenue hit $19.799 billion, growing 55.55% year over year, with non-GAAP EPS of $8.55 beating consensus by 25.88%. Mounjaro delivered $8.662 billion (+125%) and Zepbound added $4.160 billion (+80%). Management raised full-year revenue guidance to $82.0 billion to $85.0 billion.

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn't one of them. Get them here FREE.

One Reddit summary captured the mood: "Even with lower prices, demand keeps ripping." Sentiment spiked to 85 (very bullish) on April 30, then faded to neutral within 72 hours, a classic relief-bounce signature.

Realized prices fell 13% even as volume jumped 65%, a margin headwind that worsens with the Mounjaro NRDL listing in China and Zepbound cash-pay cuts. Drug pricing rhetoric tends to flare through summer political cycles. The franchise is concentrated, valuation is rich at a 34 P/E, and the Lilly Endowment disposed of 15,828 shares on May 6 near $995.

CEO David Ricks described the pipeline this way: "Foundayo will meaningfully expand the number of people who can benefit from GLP-1s." Orforglipron beat oral semaglutide head to head in The Lancet, retatrutide is advancing, and four acquisitions deepen the bench. Four directors have systematically added shares at $1,036.05, $989.12, and $919.90. The analyst consensus target stands at $1,209.14 with 24 Buy, six Hold, and one Sell ratings.

Research-oriented frameworks suggest trimming a slice of the recent bounce while keeping the core position intact, using covered calls to monetize elevated post-rally volatility, mapping a re-entry zone near the 200-day moving average or the prior base, and applying stop-loss discipline rather than a full exit. This is a cleaner seasonal trim case than most mega-cap compounders, but selling a category-defining franchise on a calendar effect rarely ages well. The bounce offers room for tactical positioning while preserving core franchise exposure. Keep an eye on the stock heading into the December 7, 2026, Investment Community Meeting.

 

This analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.